News
ImmuneRegen News
ImmuneRegen BioSciences' Homspera™ Deemed Dermally Non-Toxic
Pre-Clinical Studies Bode Well for Future Hair Loss Applications
SCOTTSDALE, Ariz., March 3 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBOE.OB), today announced their toxicity study for their proprietary compound Homspera™ showed no levels of toxicity, such as skin irritation, in tested animals. With these results, the company is moving forward in targeting male pattern baldness as a potential application for Homspera™.
The study was performed by AppTec Laboratory Services of St. Paul, MN and was designed to evaluate the allergenic potential or sensitizing capacity for the company's substance P compound. According to the AppTec results report, "ImmuneRegen BioSciences, Inc., Homspera™ [Sar9, Met (O2)11] -- Substance P ... was classified as acceptable in regard to dermal sensitization."
"Obviously we're thrilled with these test results," states Michael K. Wilhelm, president of IR BioSciences Holdings, Inc. "We're currently researching the effectiveness of Homspera™ in topical applications for conditions such as male pattern baldness and loss of hair from chemotherapy. These results put us one step closer to making these applications a reality."
About the study
The study utilized fifteen guinea pigs, ten experimental and five controls. Patches with topical doses of Homspera™ [Sar9, Met (O2)11] -- Substance P were applied to the shaved left flanks of the ten experimental guinea pigs, which were then bandaged to secure the patches. The bandaging and patches were removed after six to eight hours of exposure and each guinea pig was checked after roughly 24 hours for signs of erythema and edema. The procedure was repeated once a week for three weeks for a total of three inductions. The tested guinea pigs showed no signs of erythema or edema.
Fourteen days after completing the topical induction process, patches with topical doses were applied to the shaved right flanks of the ten experimental guinea pigs, which were then bandaged to secure the patches. Again, the bandaging and patches were removed after six to eight hours of exposure. At the 24, 48 and 72-hour marks, each testing area was wiped gently with a 70% isporpyl alcohol-soaked gauze sponge and was observed for irritation and sensitization reactions. Again, the tested guinea pigs showed no signs of erythema or edema.
About AppTec
AppTec Laboratory Services is a unique single source for the biopharmaceutical/biotechnology and medical device/medical product industries -- offering testing, contract research and development, and specialized cGMP manufacturing services.
About ImmuneRegen BioSciences, Inc.
a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Contact:
Amendola Communications for ImmuneRegen
Jan Shulman, 480-664-8412 ext. 12
jshulman@ACmarketingPR.com
or
Jodi Amendola, 480-664-8412 ext 11
jamendola@ACmarketingPR.com
###
Copyright © 2003-2008, ImmuneRegen Biosciences, Inc.
All rights reserved.